multipl
sclerosi
ms
initi
identifi
charcot
diseas
often
begin
young
adulthood
intermitt
episod
neurolog
dysfunct
includ
visual
impair
ataxia
motor
sensori
deficit
bowel
bladder
incontin
attribut
recurr
inflammatori
attack
white
matter
brain
spinal
cord
lead
accumul
perivascularli
distribut
inflammatori
cell
within
brain
spinal
cord
white
matter
beeton
et
al
first
establish
anim
model
ms
immun
monkey
central
nervou
system
cn
homogen
induc
known
experiment
autoimmun
encephalomyel
eae
sinc
pilot
anim
studi
eae
becom
accept
anim
model
ms
recent
decad
pathogen
hypothes
investig
novel
therapeut
agent
test
model
field
cn
inflamm
demyelin
therefor
eae
provid
valuabl
tool
investig
tcelldepend
pathogenesi
autoimmun
inflamm
cn
orchestr
autoimmun
demyelin
inflamm
cn
ms
patient
mice
andor
genet
modifi
mice
also
fundament
valu
explor
complex
pathogenesi
ms
eae
undoubtedli
best
anim
model
studi
autoimmun
diseas
particularli
demyelin
diseas
cn
ms
myelin
basic
protein
mbp
specif
cell
isol
peripher
lymphocyt
human
individu
ms
encephalitogen
cell
recov
circul
autoreact
cell
either
immun
anim
shown
autoreact
tcell
line
recogn
encephalitogen
part
mbp
vitro
distinguish
unprim
rat
tcell
popul
confirm
autoreact
cell
play
central
role
patholog
ms
eae
also
induc
adopt
transfer
expand
popul
myelinreact
encephalitogen
helper
th
cell
allow
dissect
immunopathogen
potenc
differ
encephalitogen
cell
popul
mosmann
coffman
postul
th
cell
classifi
two
distinct
subset
cell
produc
larg
quantiti
interferon
driven
interleukin
promot
cellular
immun
direct
intracellular
pathogen
altern
cell
secret
essenti
destruct
extracellular
parasit
mediat
humor
immun
selfreact
clone
deriv
vitro
capabl
adopt
transfer
eae
recipi
increas
level
cytokin
particularli
evid
eaem
relaps
wherea
increas
cytokin
found
remiss
ms
patient
compar
control
level
clinic
hematolog
symptom
exacerb
relapsingremit
ms
patient
follow
administr
also
observ
diseas
wherea
less
appar
diseas
cell
earlier
thought
pathogen
cell
wherea
cell
thought
confer
antiinflammatori
potenti
constitut
protect
cell
ms
eae
howev
clearcut
immunodysregul
balanc
eae
ms
may
part
hidden
complex
interact
underli
eae
ms
natur
eaem
diseas
challeng
find
mice
well
mice
lack
molecul
involv
differenti
receptor
protect
eae
instead
suscept
diseas
unexpectedli
mice
defici
compon
paradigm
vulner
eae
similarli
mice
develop
sever
clinic
manifest
eae
wherea
mice
resist
eae
discrep
conflict
data
indic
imbal
milieu
explain
overal
immunopathogen
mechan
underli
eae
ms
novel
cytokin
heavychain
homologu
subfamili
discov
comput
sequenc
chain
link
chain
subunit
anoth
subunit
heterodim
chain
form
novel
cytokin
design
therefor
delet
affect
function
cua
colleagu
verifi
essenti
induct
eae
gener
knockout
ko
mice
compar
ko
mice
furthermor
tcell
subset
driven
expand
pathogen
induc
eae
adopt
transfer
wildtyp
mice
cell
dramat
reduc
cn
mice
base
studi
research
confid
suggest
cell
distinct
novel
th
subset
exacerb
autoimmun
design
cell
cell
thcell
subset
distinct
cell
term
differenti
expans
effector
function
discoveri
cell
clarifi
cytokin
profil
ms
recent
level
produc
mbpstimul
peripher
blood
cell
obtain
ms
patient
control
shown
correl
activ
lesion
ms
patient
observ
magnet
reson
imag
mri
like
th
subset
lineag
activ
specif
cytokin
milieu
howev
produc
th
cell
de
novo
cell
receptor
express
cell
transform
growth
factor
upregul
express
therebi
confer
respons
confirm
critic
cytokin
commit
expans
vitro
vivo
mice
togeth
activ
antigenrespons
cell
develop
cell
human
cell
expos
develop
cell
product
play
role
maintain
cell
altogeth
cell
requir
gener
cell
produc
upregul
chronic
lesion
also
involv
pathogenesi
ms
thu
cell
recent
discov
uniqu
th
lineag
produc
repertoir
signatur
cytokin
includ
essenti
develop
autoimmun
diseas
ms
discoveri
transcript
factor
key
regul
cytokin
express
requir
launch
lineagespecif
transcript
program
greatli
extend
understand
thcell
lineag
commit
shown
tbet
program
commit
lineag
cytokin
product
wherea
gatabind
protein
drive
popul
expans
cytokin
product
tbet
necessari
differenti
transcript
factor
import
differenti
autoimmun
cell
eae
model
tbet
mice
resist
eae
howev
transcript
factor
mediat
induct
cell
instead
uniqu
induct
milieu
differenti
driven
distinct
transcript
factor
retino
acid
receptorrel
orphan
delet
cell
also
prevent
autoimmun
uveiti
eae
increas
express
forkhead
box
express
program
develop
function
treg
cell
human
also
induc
develop
cell
express
chemokin
transcript
factor
illustr
figur
adapt
hirota
et
al
recent
microarray
studi
lesion
ms
patient
demonstr
increas
express
confirm
cell
play
import
role
develop
inflamm
demyelin
eventu
damag
cn
recent
describ
cytokin
produc
human
almost
exclus
activ
memori
cell
induc
product
proinflammatori
cytokin
chemokin
parenchym
cell
macrophag
patient
ms
greater
number
mononuclear
cell
cerebrospin
fluid
csf
blood
previous
increas
number
express
mrna
mononuclear
cell
isol
csf
observ
patient
ms
higher
level
mrna
observ
csf
blood
highest
level
blood
detect
clinic
exacerb
data
confirm
pivot
role
ms
peripher
central
myelin
express
circul
cn
antigen
thought
express
cervic
lymph
node
trigger
convers
autoaggress
myelinreact
cell
pathogen
cell
adhes
molecul
integrin
allow
myelinreact
cell
penetr
bloodbrain
barrier
bbb
inflammatori
condit
way
activ
memori
cell
enter
cn
autoaggress
myelinreact
cell
migrat
cn
recogn
cognat
target
antigen
movement
antigenpres
cell
apc
cn
essenti
lymphocyt
reactiv
within
cn
compart
initi
inflammatori
cascad
develop
eae
subsequ
inflammatori
immun
cell
granulocyt
macrophag
attract
cn
parenchyma
mediat
tissu
inflamm
lead
demyelin
tissu
damag
brain
formerli
consid
immunoprivileg
organ
perspect
revis
last
two
decad
today
understand
damag
cn
activ
immun
cell
situ
cn
particularli
microgli
cell
deshpand
et
al
demonstr
transient
inactiv
microgli
cell
via
cellspecif
defici
express
indic
microgli
cell
crucial
maintain
autoimmun
respons
cn
major
histocompat
complex
mhc
also
known
human
leukocyt
antigen
human
class
ii
molecul
display
special
apc
eg
dendrit
cell
dc
b
cell
macrophag
wherea
mhc
class
molecul
express
cell
inflammatori
milieu
cn
microgli
cell
upregul
express
mhc
costimulatori
molecul
initi
gener
mainten
inflammatori
milieu
dc
seem
play
critic
role
antigen
present
invad
cell
releas
cytokin
chemokin
therebi
guid
entri
monocyt
lymphocyt
cell
phenotyp
similar
dc
lesion
th
cell
recruit
macrophag
releas
proinflammatori
cytokin
destruct
molecul
nitric
oxid
tumor
necrosi
factor
matrix
metalloproteinas
mmp
cell
also
directli
attack
mhc
class
iexpress
cell
oligodendrocyt
neuron
secret
destruct
molecul
degrad
myelin
consequ
cascad
tnf
receptor
signal
critic
demyelin
limit
tcell
respons
immunemedi
cn
diseas
complic
process
trigger
recruit
innat
immun
cell
gener
consist
cell
macrophag
microglia
turn
mediat
demyelin
axon
damag
lesion
autopsi
sampl
ms
patient
express
evid
perivascular
lymphocyt
astrocyt
oligodendrocyt
locat
activ
area
cn
lesion
also
identifi
acut
chronic
ms
plaqu
patient
ms
suggest
enrich
cell
activ
ms
lesion
confirm
import
role
pathogenesi
ms
cell
identifi
express
memori
tcell
marker
situ
marker
investig
includ
chemokin
receptor
rorc
variant
central
transcript
factor
develop
microarray
analysi
ms
lesion
also
demonstr
increas
transcript
gene
encod
inflammatori
cytokin
particularli
associ
downstream
pathway
signific
increas
mrna
protein
express
found
lesion
tissu
compar
nonles
tissu
activ
macrophagesmicroglia
shown
import
sourc
activ
chronic
activ
ms
lesion
matur
dc
preferenti
locat
perivascular
cuff
activ
lesion
data
express
ms
lesion
improv
understand
pathogenesi
ms
also
evid
ms
endotheli
cell
express
high
level
permeabl
nonm
endotheli
cell
perivascular
dc
also
express
high
level
granzym
b
inflammatori
lesion
polar
cell
cell
cell
transmigr
effici
across
bbb
endotheli
cell
bbbec
lead
destruct
human
neuron
initi
cn
inflamm
thcell
recruit
similarli
express
bbbec
examin
ms
lesion
shown
disrupt
bbb
tight
junction
vitro
vivo
transsign
may
also
play
role
autoimmun
inflamm
cn
mainli
regul
earli
express
adhes
molecul
possibl
via
cellular
network
bbb
ifergan
et
al
demonstr
subset
monocyt
migrat
across
inflam
human
bbb
differenti
dc
influenc
bbbsecret
granulocytemacrophag
colonystimul
factor
gmcsf
dc
produc
promot
prolifer
expans
distinct
popul
cell
abund
dc
situ
strongli
associ
microvascular
bbbec
within
acut
ms
lesion
signific
number
cell
perivascular
infiltr
astrocyt
play
signific
physiolog
role
cn
homeostasi
act
bridg
cn
immun
system
astrocyt
also
contribut
complex
interact
cn
inflamm
function
synergist
manner
induc
express
astrocyt
astrocyt
upregul
express
gene
protein
cell
consist
astrocyt
capac
express
subunit
common
subunit
subunit
two
cell
type
cocultur
da
sarma
et
al
demonstr
increas
express
cn
mice
eae
constitut
express
function
mous
cn
tissu
also
identifi
express
astrocyt
microglia
vitro
studi
secret
chemokin
upregul
cell
suggest
upregul
chemokin
glial
cell
result
signal
constitut
express
et
al
demonstr
suppressor
cytokin
signal
particip
function
cn
neg
feedback
regul
use
mous
model
small
interf
rna
sirna
knockdown
delet
mice
loss
function
show
enhanc
signal
astrocyt
via
activ
mapk
pathway
indic
astrocyt
act
target
cell
cn
similarli
kang
et
al
construct
specif
delet
mutant
critic
compon
requir
signal
mice
eae
examin
cn
inflamm
endotheli
cell
macrophag
microglia
neuroectoderm
neuron
astrocyt
oligodendrocyt
mice
cell
show
normal
infiltr
cn
fail
recruit
lymphocyt
neutrophil
macrophag
therefor
astrocyt
critic
leukocyt
recruit
eae
interestingli
merkler
et
al
demonstr
macrophag
respond
milieu
neutrophil
respond
cytokin
marmoset
monkey
model
eae
also
show
dens
accumul
b
lymphocyt
mhciiexpress
macrophagesmicroglia
earli
activ
macrophag
site
perivascular
parenchym
lesion
neocortex
subcort
white
matter
indic
inflammatori
respons
especi
macrophag
microglia
activ
may
regul
differ
gray
matter
area
primat
brain
summari
dc
peripher
tissu
microglia
cn
respons
cytokin
polar
expans
cell
complex
interact
cell
differ
dc
microglia
astrocyt
peripher
dc
includ
neutrophil
macrophag
contribut
immunopathogenesi
eae
ms
ko
mice
impair
cell
protect
eae
increas
suscept
progress
relaps
onset
ms
impli
role
develop
eae
ms
eae
abolish
virusexpress
virusexpress
chronic
relaps
eae
therefor
cytokin
environ
convert
diseasepromot
condit
diseaselimit
condit
local
express
herp
simplex
viru
vector
deliv
brain
moreov
increas
express
glial
cell
associ
reduc
sever
eae
suggest
upregul
cytokin
inhibit
propag
inflamm
eaem
encephalitogen
cell
cell
wellknown
regulatori
cell
treg
retain
potenti
inhibit
autoimmun
respons
protect
inflammatori
injuri
key
cytokin
gener
treg
treg
primarili
involv
regul
cell
also
regul
function
cell
distinct
drawn
gener
pathogen
cell
induc
autoimmun
gener
treg
inhibit
autoimmun
tissu
injuri
although
eae
consid
classic
diseas
propos
predominantli
driven
recent
singh
et
al
demonstr
overexpress
cell
exacerb
eae
moreov
genet
antibodi
studi
indic
absenc
reduc
incid
sever
eae
collect
find
studi
indic
role
may
depend
natur
immun
respons
occur
brain
may
overcom
inhibitori
effect
gener
prevent
inflamm
site
pure
cell
myelin
oligodendrocyt
glycoprotein
mog
immun
mice
polar
deplet
product
adopt
transfer
mice
induc
eae
suggest
reciproc
interact
among
cytokin
enrol
activ
involv
associ
immun
cell
interestingli
cell
combin
cell
fulli
induc
eae
diseas
liu
et
al
also
demonstr
loss
th
cell
result
intrins
development
defect
render
mice
resist
cn
inflammatori
diseas
requir
product
cell
gener
doubl
posit
cell
express
cell
traffick
cn
tissu
suggest
may
therapeut
target
modul
cn
autoimmun
diseas
cell
facilit
entranc
cell
cn
eae
encephalitogen
cell
line
induc
recruit
host
cell
cn
initi
eae
report
stromn
et
al
show
signific
differ
regul
inflamm
brain
spinal
cord
depend
differ
ratio
demonstr
specif
tcell
popul
target
differ
myelin
epitop
character
differ
ratio
eae
therefor
cell
potenti
reciproc
regul
cell
eae
type
bundl
cytokin
belong
famili
function
growth
hormon
like
cytokin
antigenrespons
differenti
phase
cell
enter
amplif
stage
play
pivot
role
expans
differenti
lineag
provid
autocrin
paracrin
stimulu
cell
clonal
expans
also
promot
express
differenti
cell
play
import
role
stabil
lineag
presenc
although
effect
observ
administ
eae
progress
administr
boost
natur
killer
nk
cell
function
induct
eae
includ
secret
therefor
affect
nk
cell
variou
effect
initi
progress
eae
altern
famili
member
neg
regul
cell
differenti
prevent
inflammatori
demyelin
eae
model
drive
expans
differenti
cell
induc
express
three
key
molecul
transcript
factor
cmaf
cytokin
ico
moreov
cmaf
express
transactiv
product
act
autocrin
growth
factor
expans
andor
mainten
cell
ico
also
promot
cell
element
essenti
loss
cmaf
signal
ico
reduc
frequenc
differenti
cell
figur
exacerb
eae
demonstr
mice
interestingli
mice
markedli
reduc
cn
inflammatori
infiltr
indic
downregul
phenomena
recent
novel
effector
tcell
subset
cell
identifi
abil
tcell
subset
induc
eae
current
investig
et
al
gener
mogspecif
cell
vitro
directli
character
encephalitogen
potenc
adopt
transfer
found
mogspecif
cell
cell
induc
eae
interestingli
tcell
subset
induc
diseas
distinct
patholog
manner
suggest
differ
effector
th
subset
induc
eae
differ
impli
patholog
heterogen
ms
lesion
might
partli
attribut
variou
characterist
myelinreact
effector
cell
author
also
suggest
ms
might
diseas
caus
multipl
distinct
myelinreact
effector
cell
diseas
induc
cell
anim
exhibit
symptom
atyp
eae
includ
ataxia
sever
imbal
weight
loss
associ
high
mortal
anim
mixtur
atyp
typic
eae
symptom
cell
recov
cn
appear
transfer
cell
produc
ident
cell
popul
seem
drift
vivo
transfer
nowak
et
al
recent
demonstr
like
cell
cultur
presenc
cell
produc
cell
gener
vitro
ex
vivopurifi
cell
produc
data
show
neutral
defici
attenu
diseas
correl
reduct
cell
macrophag
cn
author
also
confirm
role
develop
progress
eae
implic
cytokin
contribut
inflammatori
diseas
togeth
cell
cell
treg
exert
repress
effect
cell
cell
stimulatori
effect
cell
suppress
eae
ms
howev
cell
play
dual
role
eae
understand
pathophysiolog
neurodegen
process
ms
led
develop
novel
therapeut
strategi
sinc
earli
diseasemodifi
drug
introduc
select
manag
ms
includ
glatiram
acet
ga
becom
standard
treatment
relapsingremit
ms
recommend
previous
made
multipl
sclerosi
therapi
consensu
group
mstcg
use
diseasemodifi
drug
therapi
remain
valid
hermmer
hartung
publish
appar
review
develop
ration
therapi
ms
therefor
discuss
four
domain
novel
immunomedi
therapeut
use
ms
current
statu
first
domain
includ
immunosuppress
agent
mitoxantron
laquinimod
cladribin
mylinax
teriflunomid
probabl
via
suppress
product
second
domain
includ
immunomodulatori
agent
cytokin
inhibitor
agent
deplet
specif
immun
cell
subset
alemtuzumab
human
monoclon
antibodi
mab
target
express
b
cell
produc
longterm
tcell
deplet
rituximab
target
deplet
human
b
cell
agent
select
block
coreceptor
costimul
daclizumab
mab
inhibit
activ
cell
induc
regulatori
immun
cell
third
domain
involv
develop
migrationmodifi
therapi
agent
affect
adhes
molecul
natalizumab
mab
block
late
antigen
sphingosin
receptor
agonist
fingolimod
fourth
domain
includ
neuroprotect
agent
associ
immunomodul
includ
broadspectrum
immunomodul
statin
ppar
agonist
eg
pioglitazon
gemfibrozil
sex
hormon
estriol
fumar
minocyclin
erythropoietin
epo
effect
treatment
eae
ms
clinic
introduc
treat
patient
ms
base
abil
shift
respons
respons
howev
microarray
studi
indic
number
gene
patient
ms
upregul
cytokin
associ
differenti
cell
lymphocyt
rather
lymphocyt
suggest
shift
may
therapeut
mechan
ms
therapi
also
reduc
mrna
level
inhibit
human
cell
differenti
axi
could
anoth
target
therapi
product
innat
immun
cell
shown
play
critic
role
immunoregulatori
role
eae
inhibit
cell
eae
mice
ms
patient
besid
galligan
et
al
evid
mice
exhibit
earlier
diseas
onset
rapid
progress
eae
compar
mice
eae
mice
eae
increas
number
leukocyt
infiltr
affect
brain
increas
percentag
cell
cn
augment
autoreact
cell
suggest
act
suppress
product
autoimmuneinduc
cell
develop
diseas
well
modul
proinflammatori
addit
therapeut
effect
probabl
attribut
induct
regulatori
cytokin
furthermor
axtel
et
al
design
delic
studi
clarifi
role
mseae
likewis
demonstr
effect
reduc
eae
symptom
transfer
cell
transfer
exacerb
diseas
cell
transfer
effect
treatment
eae
correl
augment
product
differ
eae
amount
unaffect
treatment
likewis
high
level
serum
peopl
rrm
associ
fail
therapi
characterist
might
contribut
explor
logic
biomark
predict
assess
respons
popular
therapi
ms
although
b
cell
may
dual
role
pathogenesi
ms
contribut
induct
autoimmun
respons
also
mediat
resolut
cn
inflammatori
infiltr
howev
ramgolam
et
al
demonstr
supernat
transfer
b
cell
inhibit
cell
differenti
suppress
gene
express
rorc
secret
likewis
also
induc
b
cell
secret
may
mediat
regulatori
potent
thu
exert
therapeut
effect
least
part
target
b
cell
function
contribut
autoimmun
pathogenesi
rr
ms
may
uncov
extra
mechan
bcell
contribut
autoimmun
effect
provid
novel
target
futur
select
treatment
ms
glatiram
acet
ga
copaxon
copolym
exert
clinic
respons
ms
patient
via
modul
reduc
express
ensur
stabl
express
peripher
blood
mononuclear
cell
pbmc
moreov
ga
enhanc
suppress
effect
treg
eae
ms
studi
human
dc
shown
ga
modul
product
inflammatori
mediat
without
affect
dc
matur
immunostimulatori
potenti
dc
expos
ga
secret
low
level
factor
respons
lipopolysaccharid
trigger
ligand
human
dc
expos
ga
also
induc
effector
cell
increas
express
result
show
apc
includ
dc
essenti
gamedi
shift
thcell
phenotyp
indic
dc
import
target
immunomodulatori
effect
ga
patient
ms
show
threefold
fourfold
increas
express
subunit
integrin
normal
express
activ
lymphocyt
monocyt
cell
type
csf
circul
elovaara
et
al
confirm
methylprednisolon
reduc
adhes
molecul
blood
csf
patient
ms
impli
target
leukocyt
traffick
may
possibl
therapeut
strategi
ms
therefor
natalizumab
human
mab
direct
adhes
complex
introduc
treatment
ms
reduc
risk
sustain
progress
disabl
rate
clinic
relaps
patient
relaps
ms
howev
clinic
trial
two
natalizumabtr
ms
patient
develop
progress
multifoc
leukoencephalopathi
pml
result
voluntari
remov
drug
market
februari
retrospect
safeti
evalu
subsequ
conduct
natalizumab
consequ
return
market
monotherapi
juli
treatment
relaps
ms
howev
case
pml
report
subsequ
natalizumabtr
ms
patient
april
evid
risk
develop
pml
ms
patient
natalizumab
tysabri
almost
time
higher
patient
take
drug
two
year
prior
histori
immunosuppress
use
test
posit
antibodi
jc
viru
compar
patient
none
three
risk
factor
instead
current
convinc
evid
natalizumabassoci
pml
restrict
combin
therapi
diseasemodifi
immunosuppress
agent
nevertheless
natalizumab
use
must
restrict
indic
patient
mitoxantron
cytotox
drug
immunomodulatori
properti
use
treat
progress
form
ms
mitoxantron
increas
ex
vivo
product
cytokin
signific
chang
express
pbmc
cell
indic
immunomodul
afford
mitoxantron
treatment
ms
act
enhanc
cytokin
current
headtohead
race
approv
initi
develop
two
spotlight
oral
immunomodulatori
cladribin
figur
fingolimod
novarti
modul
spotlight
complet
phase
iii
trial
approv
us
food
drug
administr
first
oral
firstlin
treatment
relaps
ms
mainli
express
immun
cell
neuron
cell
endotheli
cell
smooth
muscl
cell
key
role
angiogenesi
neurogenesi
regul
immun
cell
traffick
endotheli
barrier
function
vascular
tone
demonstr
genet
delet
murin
model
immunomodulatori
effect
fingolimod
act
two
pathway
one
pathway
inhibit
function
facilit
ccchemokin
receptor
mediat
retent
lymphocyt
lymph
node
includ
cell
central
memori
cell
effect
memori
cell
significantli
reduc
infiltr
inflammatori
cell
cn
reduc
number
autoreact
cell
recircul
via
lymph
blood
cn
second
pathway
prohibit
neuroinflamm
via
modul
express
oligodendrocyt
neuron
astrocyt
microglia
anoth
oral
immunomodulatori
drug
cladribin
synthet
chlorin
deoxyadenosin
analog
activ
intracellular
phosphoryl
specif
cell
type
result
preferenti
sustain
reduct
peripher
b
lymphocyt
mimick
immunedefici
statu
hereditari
adenosin
deaminas
defici
oral
administ
cladribin
show
significantli
efficaci
patient
rrm
rel
placebo
oral
cladribin
reduc
relaps
impact
disabl
progress
mri
outcom
marker
patient
rrm
nevertheless
exactli
weight
benefit
novel
immunomodultori
agent
potenti
risk
necessari
must
monitor
continu
advanc
identifi
uniqu
therapeut
target
ms
instig
numer
phase
ii
phase
iii
clinic
trial
exampl
trial
variou
mab
includ
direct
alemtuzumab
daclizumab
rituximab
trial
diseasemodifi
therapi
teriflunomid
laquinimod
fumar
exampl
alemtuzumab
human
mab
target
surfac
molecul
tcell
popul
cellular
compon
immun
system
thymocyt
b
cell
monocyt
offner
report
estrogen
deriv
exert
neuroimmunoprotect
effect
eae
upregul
express
contribut
activ
treg
suggest
therapeut
applic
estrogen
ms
papenfuss
et
al
also
demonstr
estriol
pregnancyspecif
estrogen
therapeut
efficaci
ms
eae
confirm
protect
mice
eae
induc
dc
increas
express
inhibitori
costimulatori
marker
deviat
toward
phenotyp
peroxisom
proliferatoractiv
receptor
ppar
member
nuclear
hormon
receptor
superfamili
includ
receptor
steroid
retinoid
thyroid
hormon
involv
immun
respons
natarajan
et
al
demonstr
agonist
inhibit
eae
block
product
signal
cell
differenti
kanakasabai
et
al
demonstr
agonist
amelior
eae
block
product
cell
inhibit
eae
agonist
also
associ
reduct
increas
express
cn
lymphoid
organ
indic
agonist
modul
respons
eae
suggest
use
treatment
ms
autoimmun
diseas
minocyclin
oral
semisynthet
tetracyclin
antibiot
penetr
cn
interest
pleiotrop
biolog
function
neuroprotect
effect
includ
demyelin
diseas
ms
nikodemova
et
al
shown
minocyclin
attenu
eae
rat
reduc
tcell
infiltr
spinal
cord
downregul
cell
without
modifi
product
domin
cytokin
zabad
et
al
demonstr
cohort
studi
impact
oral
minocyclin
clinic
mri
outcom
serum
immun
molecul
month
openlabel
minocyclin
treatment
relaps
occur
month
level
subunit
elev
month
treatment
might
counteract
proinflammatori
effect
downregul
activ
reduc
minocyclin
treatment
brine
et
al
demonstr
epo
mediat
neuroprotect
experiment
ischem
brain
injuri
agnello
et
al
shown
epo
exert
antiinflammatori
effect
amelior
eae
yuan
et
al
also
demonstr
epo
retain
immunomodulatori
capac
peripheri
inflam
spinal
cord
promot
massiv
expans
treg
cell
inhibit
polar
abrog
prolifer
antigenpres
dc
observ
significantli
reduc
level
cell
cn
significantli
increas
proport
splenic
treg
epotr
mogea
mice
also
demonstr
mogspecif
tcell
prolifer
suppress
epotr
group
immunomodulatori
mechan
immunomedi
therapeut
agent
fulli
understood
report
current
understand
immunomodulatori
effect
clinic
proven
clinic
tri
agent
potenti
candid
agent
decoy
receptor
select
review
immunomodul
eae
ms
demjen
et
al
show
neutral
fasl
promot
axon
regener
function
improv
injur
anim
model
suggest
therapeut
strategi
may
constitut
potent
futur
treatment
human
spinal
injuri
recogn
member
tnfr
superfamili
predominantli
express
tumor
cell
allow
evad
immun
attack
solubl
receptor
bind
member
tnf
famili
competit
inhibit
bind
tnf
tnfr
fasl
light
tnflike
molecul
confirm
ligand
bind
fasl
inhibit
faslinduc
apoptosi
also
recent
shown
counteract
effect
cell
interf
faslfa
interact
demonstr
amelior
eae
directli
counteract
inflamm
downregul
cell
situ
impli
downregul
respons
inhibit
inflamm
cn
situ
eae
block
ligandreceptor
interact
fasfasl
andor
therefor
introduc
anoth
immunomodulatori
molecul
potenti
candid
consider
clinic
treatment
ms
summari
figur
immunomodulatori
agent
neuroprotect
therapi
ms
great
valu
clinic
agent
test
clinic
trial
preclin
studi
develop
novel
therapeut
strategi
ms
ms
common
disabl
cn
diseas
young
adult
character
recurr
relaps
andor
progress
attribut
multifoc
inflamm
demyelin
axon
patholog
within
brain
andor
spinal
cord
effector
th
cell
play
wellrecogn
role
initi
autoimmun
tissu
inflamm
autoreact
effector
cell
establish
associ
pathogenesi
disord
howev
model
thought
driven
cell
mice
lack
hallmark
cytokin
protect
eae
tend
display
enhanc
suscept
diseas
identif
cell
shed
light
appar
discrep
like
cell
polar
cell
capac
caus
inflamm
autoimmun
diseas
defici
cytokin
cytokin
induc
resist
eae
impli
cell
chief
contributor
eaem
wherea
cell
consist
transfer
eae
diseas
komiyama
et
al
demonstr
eae
significantli
suppress
mice
manifest
delay
onset
reduc
maximum
sever
amelior
histolog
chang
earli
recoveri
howev
outcom
vari
differenti
andor
function
cell
block
clinic
trial
human
autoimmun
diseas
notabl
success
psoriasi
crohn
diseas
neg
result
relapsingremit
ms
strategi
inhibit
respons
even
less
support
preclin
studi
anim
model
data
rais
question
whether
ms
mediat
sole
cell
sole
cell
whether
mediat
pathway
whether
perhap
mediat
neither
pathway
grow
evid
autoreact
cell
particularli
cell
particip
pathophysiolog
ms
although
exact
role
cell
develop
ms
lesion
well
understood
appear
effector
tcell
popul
caus
cn
inflamm
demyelin
lesion
ms
eae
increas
understand
immunopathogen
role
cell
treg
mseae
facilit
develop
novel
immunomodulatori
therapeut
approach
ms
treatment
ms
alway
hamper
untoward
advers
effect
caus
immunosuppress
agent
natalizumab
current
approv
diseasemodifi
treatment
achiev
effect
primarili
block
proinflammatori
respons
nonspecif
manner
limit
clinic
efficaci
call
differenti
specif
therapeut
approach
confid
say
ga
mitoxantron
fairli
clinic
effect
ms
patient
addit
estrogen
minocyclin
also
shown
benefit
treatment
ms
establish
protect
effect
epo
eae
evid
requir
use
clinic
treatment
ms
immunomodulatori
therapeut
agent
current
clinic
trial
includ
fingolimod
alemtuzumab
rituximab
addon
therapi
extens
clinic
applic
potenti
novel
immunomodulatori
therapeut
agent
close
scrutini
near
futur
